From: Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study
Treatment | Mean change | Treatment contrasts | ||||
---|---|---|---|---|---|---|
Difference | 95% CI | P-value* | ||||
CCQ variable | ||||||
Overall mean | AZD3199 200 μg od | −0.38 | AZD3199 200 vs Placebo | −0.262 | −0.457, -0.067 | 0.009 |
AZD3199 400 μg od | −0.30 | AZD3199 400 vs Placebo | −0.178 | −0.369, 0.014 | 0.068 | |
AZD3199 800 μg od | −0.36 | AZD3199 800 vs Placebo | −0.240 | −0.435, -0.045 | 0.016 | |
Formoterol 9 μg bid | −0.36 | Formoterol 9 vs Placebo | −0.234 | −0.427, -0.040 | 0.018 | |
Placebo | −0.12 | AZD3199 200 vs Formoterol 9 | −0.028 | −0.219, 0.162 | 0.770 | |
AZD3199 400 vs Formoterol 9 | 0.056 | −0.132, 0.243 | 0.559 | |||
AZD3199 800 vs Formoterol 9 | −0.007 | −0.198, 0.184 | 0.945 | |||
AZ Diary card COPD Symptoms | ||||||
Total Score (0–16) | AZD3199 200 μg od | −0.94 | AZD3199 200 vs Placebo | −0.480 | −1.011, 0.051 | 0.076 |
AZD3199 400 μg od | −0.94 | AZD3199 400 vs Placebo | −0.473 | −1.000, 0.054 | 0.078 | |
AZD3199 800 μg od | −1.19 | AZD3199 800 vs Placebo | −0.723 | −1.254, -0.192 | 0.008 | |
Formoterol 9 μg bid | −0.62 | Formoterol 9 vs Placebo | −0.152 | −0.685, 0.380 | 0.574 | |
Placebo | −0.46 | AZD3199 200 vs Formoterol 9 | −0.327 | −0.852, 0.197 | 0.220 | |
AZD3199 400 vs Formoterol 9 | −0.321 | −0.841, 0.200 | 0.226 | |||
AZD3199 800 vs Formoterol 9 | −0.570 | −1.095, -0.046 | 0.033 | |||
SGRQ-C Scores | ||||||
Total Score | AZD3199 200 μg od | −5.61 | AZD3199 200 vs Placebo | −3.01 | −7.31, 1.28 | 0.169 |
AZD3199 400 μg od | −8.18 | AZD3199 400 vs Placebo | −5.59 | −9.78, -1.40 | 0.009 | |
AZD3199 800 μg od | −4.63 | AZD3199 800 vs Placebo | −2.03 | −6.29, 2.23 | 0.350 | |
Formoterol 9 μg bid | −4.93 | Formoterol 9 vs Placebo | −2.33 | −6.65, 1.99 | 0.289 | |
Placebo | −2.60 | AZD3199 200 vs Formoterol 9 | −0.68 | −4.89, 3.53 | 0.751 | |
AZD3199 400 vs Formoterol 9 | −3.25 | −7.34, 0.83 | 0.118 | |||
AZD3199 800 vs Formoterol 9 | 0.30 | −3.86, 4.47 | 0.886 |